Singapore: Scientists claim to have found a specific biomarker for Chikungunya, which they say could serve as an early and accurate prognosis of patients at risk from the mosquito-borne infectious disease endemic to Southeast Asia and Africa. There is no clinically-approved vaccine or treatment for chikungunya fever, which is characterised by persistent joint pains that linger for months. Most patients recover within a week but those with a weak immune system may also die from it. Scientists at A*Star`s (Agency for Science, Technology and Research) Singapore Immunology Network (SIgN) discovered that patients who respond to the disease at the onset with high levels of IgG3 -- a naturally-acquired antibody – are protected from the more severe form of chikungunya fever.
Communal riots in Saharanpur fixed?
Glasgow: India`s golden girls shine at CWG
Petrol prices expected to fall by July 31
Delhi auto drivers on a day long strike against Delhi Police